https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Upper limb strength decreased significantly over 12 and 24months. FVC declined significantly over 12months, but not 24months. FF increased over 12 and 24months, although not with statistical significance. A significant increase in C-CSA was observed at 12 but not 24months. Blood SMN protein levels were stable over 12 and 24months. These data demonstrate that the MFM32, MyoGrip, MyoPinch, and ActiMyo enable the detection of a significant decline in patients with Type 2 and 3 SMA over 12 or 24months. These data demonstra
Like
Comment
Share
